TrademarkDir
GENZELENT
DEAD

Serial Number

90382660

Owner

SAREPTA THERAPEUTICS, INC.

Attorney

Maury M. Tepper, III

Filing Date

Dec 15, 2020

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

GENZELENT Trademark

Serial Number: 90382660

GENZELENT is a trademark filed by SAREPTA THERAPEUTICS, INC. on December 15, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

SAREPTA THERAPEUTICS, INC. (109 trademarks)

215 FIRST STREET, SUITE 7
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

December 15, 2020

Registration Date

Not Registered

Published for Opposition

July 13, 2021

Goods & Services

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 10, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 9, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 21, 2023 EXRA
SOU EXTENSION 3 GRANTED
Feb 17, 2023 EX3G
SOU EXTENSION 3 FILED
Feb 17, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 17, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 26, 2022 EXRA
SOU EXTENSION 2 GRANTED
Aug 24, 2022 EX2G
SOU EXTENSION 2 FILED
Aug 24, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 24, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 19, 2022 EXRA
SOU EXTENSION 1 GRANTED
Feb 17, 2022 EX1G
SOU EXTENSION 1 FILED
Feb 17, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 17, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 7, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 13, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jul 13, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 23, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 4, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 3, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 3, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 31, 2021 GNRN
NON-FINAL ACTION E-MAILED
May 31, 2021 GNRT
NON-FINAL ACTION WRITTEN
May 31, 2021 CNRT
ASSIGNED TO EXAMINER
May 29, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2021 NWOS
NEW APPLICATION ENTERED
Dec 18, 2020 NWAP

Related Trademarks

More from this Owner

RYSBEVI

RYSBEVI

RYSBEVI

RYSBEVI

SAREPTACADEMY

SAREPTACADEMY

SAREPTACADEMY

SAREPTACADEMY

BETRUVO

BETRUVO

BETRUVO

BETRUVO